US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

15.39

-0.1300-0.84%

Post-market: 15.520.1294+0.84%19:56 EDT

Volume:1.01M

Turnover:15.81M

Market Cap:1.97B

PE:-4.70

High:16.05

Open:15.32

Low:15.03

Close:15.52

52wk High:22.67

52wk Low:11.00

Shares:128.19M

Float Shares:60.29M

Volume Ratio:1.05

T/O Rate:1.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2762

EPS(LYR):-4.9816

ROE:-81.72%

ROA:-34.63%

PB:4.33

PE(LYR):-3.09

Loading ...

Overview Company News Filings

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug

Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Generate Biomedicines Initiated at Overweight by Piper Sandler

Generate Biomedicines Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $20

THOMSON REUTERS

Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating

MT Newswires Live

Generate Biomedicines Initiated at Buy by Guggenheim

Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target

MT Newswires Live

Generate Biomedicines initiated with a Buy at Guggenheim

Generate Biomedicines initiated with an Overweight at Piper Sandler

Generate Biomedicines initiated with a Buy at Goldman Sachs

Generate Biomedicines Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $24

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/GENB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":15.39,"timestamp":1789070400000,"preClose":15.52,"halted":0,"volume":1008612,"hourTrading":{"tag":"盘后","latestPrice":15.5194,"preClose":15.39,"latestTime":"19:56 EDT","volume":5393,"amount":83096.4558,"timestamp":1789084590213,"change":0.1294,"changeRate":0.008408,"amplitude":0.028499},"delay":0,"changeRate":-0.00837628865979375,"floatShares":60288200,"shares":128192484,"eps":-3.27625,"marketStatus":"Closed","change":-0.13,"latestTime":"09-10 16:00:00 EDT","open":15.32,"high":16.05,"low":15.03,"amount":15806075.650992,"amplitude":0.065722,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.27625,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":5,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":15.52,"preHourTrading":{"tag":"盘前","latestPrice":15.5,"preClose":15.52,"latestTime":"09:25 EDT","volume":3156,"amount":48553.220052,"timestamp":1789046700060,"change":-0.02,"changeRate":-0.001289,"amplitude":0.020619},"postHourTrading":{"tag":"盘后","latestPrice":15.5194,"preClose":15.39,"latestTime":"19:56 EDT","volume":5393,"amount":83096.4558,"timestamp":1789084590213,"change":0.1294,"changeRate":0.008408,"amplitude":0.028499},"volumeRatio":1.045688},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":60288200,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":1.045688,"shares":128192484,"dividePrice":0,"high":16.05,"amplitude":0.065722,"preClose":15.52,"low":15.03,"week52Low":11,"pbRate":"4.33","psRate":"74.50","week52High":22.6699,"institutionHeld":0,"latestPrice":15.39,"eps":-3.27625,"divideRate":0,"volume":1008612,"delay":0,"ttmEps":-3.27625,"open":15.32,"prevYearClose":16,"prevWeekClose":16.39,"prevMonthClose":15.27,"prevQuarterClose":16.87,"fiveDayClose":16.28,"twentyDayClose":15.09,"sixtyDayClose":13.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GENB","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-05-07","symbol":"GENB","fiscalQuarterEnding":"2026/03","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1782360000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-09-09","current":-4.697444,"percent":0.242424,"low":-11.002825,"twenty":-8.759069,"median":-8.030177,"eighty":-7.545823,"high":-6.883628,"avg":-8.174318,"sd":0.741271,"marketCap":2040803732},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-17","current":-7.910979,"twenty":-8.036451,"median":-7.697677,"eighty":-7.419131,"marketCap":1607147034},{"date":"2026-04-24","current":-8.067818,"twenty":-8.0628,"median":-7.732183,"eighty":-7.42164,"marketCap":1639009584},{"date":"2026-05-01","current":-7.923526,"twenty":-8.036451,"median":-7.810602,"eighty":-7.471829,"marketCap":1609696038},{"date":"2026-05-08","current":-8.522653,"twenty":-8.180743,"median":-7.816876,"eighty":-7.489394,"marketCap":1731410980},{"date":"2026-05-15","current":-8.844872,"twenty":-8.266063,"median":-7.84197,"eighty":-7.500687,"marketCap":1971654609},{"date":"2026-05-22","current":-8.039526,"twenty":-8.266063,"median":-7.83256,"eighty":-7.486839,"marketCap":1792130926},{"date":"2026-05-29","current":-7.527711,"twenty":-8.282375,"median":-7.816876,"eighty":-7.489371,"marketCap":1678039615},{"date":"2026-06-05","current":-8.453579,"twenty":-8.282375,"median":-7.810602,"eighty":-7.474106,"marketCap":1884429514},{"date":"2026-06-12","current":-7.435699,"twenty":-8.229473,"median":-7.788352,"eighty":-7.435629,"marketCap":1657528818},{"date":"2026-06-18","current":-7.976268,"twenty":-8.211907,"median":-7.788092,"eighty":-7.435594,"marketCap":1778029753},{"date":"2026-06-26","current":-9.442705,"twenty":-8.343203,"median":-7.810602,"eighty":-7.4449,"marketCap":2104920587},{"date":"2026-07-02","current":-9.488711,"twenty":-8.508838,"median":-7.810602,"eighty":-7.463837,"marketCap":2115175986},{"date":"2026-07-10","current":-9.040154,"twenty":-8.869967,"median":-7.84197,"eighty":-7.484992,"marketCap":2015185848},{"date":"2026-07-17","current":-7.855502,"twenty":-8.85402,"median":-7.855502,"eighty":-7.488094,"marketCap":1751109331},{"date":"2026-07-24","current":-7.953265,"twenty":-8.801131,"median":-7.883241,"eighty":-7.493159,"marketCap":1772902053},{"date":"2026-07-31","current":-8.06828,"twenty":-8.626167,"median":-7.861253,"eighty":-7.503197,"marketCap":1798540550},{"date":"2026-08-07","current":-7.489636,"twenty":-8.522653,"median":-7.910979,"eighty":-7.503197,"marketCap":1780593602},{"date":"2026-08-14","current":-8.114449,"twenty":-8.453579,"median":-7.917253,"eighty":-7.52196,"marketCap":1929137113},{"date":"2026-08-21","current":-8.632737,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"marketCap":2052355451},{"date":"2026-08-28","current":-8.513962,"twenty":-8.702922,"median":-7.964766,"eighty":-7.527711,"marketCap":2024117915},{"date":"2026-09-04","current":-8.821696,"twenty":-8.713719,"median":-7.99352,"eighty":-7.544963,"marketCap":2097278804},{"date":"2026-09-09","current":-8.584147,"twenty":-8.759069,"median":-8.030177,"eighty":-7.545823,"marketCap":2040803732}],"updateTime":1789096323396},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625494368","title":"Generate Biomedicines publishes corporate presentation on programmable biology drug design platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625494368?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:07","pubTimestamp":1775646420,"startTime":"0","endTime":"0","summary":"Generate Biomedicines outlined strategy to use generative biology and scaled lab automation to lower drug-discovery time to proof of concept to 3-5 years from 6-8 years.Company also projected cost to proof of concept of $25-60 million versus $380 million for traditional discovery.Lead program GB-0895, anti-TSLP monoclonal antibody, is positioned for twice-yearly dosing with reported human half-life of 98 days.GB-0895 is in Phase 3 development in severe asthma, with Phase 1b results in moderate-to-severe COPD slated for 1H 2026.Pipeline catalyst slate includes planned Phase 1 first-patient-dosed starts in 1H 2026 for GB-4362, an MMAE toxin neutralizer, in first-line metastatic urothelial cancer, alongside GB-5267 MUC-16 armored CAR-T in relapsed or refractory platinum-resistant ovarian cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1MDjP1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622006872","title":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2622006872","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622006872?lang=en_us&edition=fundamental","pubTime":"2026-03-26 01:52","pubTimestamp":1774461124,"startTime":"0","endTime":"0","summary":"BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug** Morgan Stanley initiates drug developer Generate Biomedicines GENB.O with an \"overweight\" rating as research quiet period ends** Company secured a valuation of nearly $1.91 bln at open after its debut on the Nasdaq late last month** Brokerage cites, \"we see GENB's lead asset, GB-0895, as having best-in-class potential vs. blockbuster generating commercial benchmarks\"** GB-0895 is GENB's lead product to treat severe asthma which is being tested in a late-stage trial ** \"We believe GB-0895 has credible best-in-class potential in severe asthma by improving on a validated mechanism rather than reinventing the biology\"- MS** Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor were the underwriters for GENB's offering** As of last close, stock down 24% since its debut on Feb. 27  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D1S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","GENB","LU0053671581.USD","BK4139","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077173","title":"Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077173","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077173?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:45","pubTimestamp":1774449917,"startTime":"0","endTime":"0","summary":"Salveen Richter, an analyst from Goldman Sachs, has initiated a new Buy rating on Generate Biomedicines, Inc. (GENB). Salveen Richter has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/generate-biomedicines-differentiated-ai-driven-protein-platform-with-gb-0895-asthma-lead-and-emerging-oncology-upside-justifies-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIX","CHAT","AIPO","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVAH","ELVN","HAL","AMZP","CALM","HD","CVI","AMZU","DINO","BRZE","FRPT","APEI","BWXT","CNM","ACAD","GLW","ARE","BCAX","CEG","AFG","AZYY","DK","FIG","ADUS","CDE","KBH","MTDR","AMZN","BTM","FIGG","GENB","INSM","CEGX","AMZD","BXP","AARD","BP","BZAI","ESE","AIR","BAM","DG","USAW.SI","EVGO","FANG","BPH","CVX","AVTX","ABSI"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621706775","title":"Generate Biomedicines Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706775?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:02","pubTimestamp":1774357320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 09:02 ET (13:02 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621205062","title":"Generate Biomedicines Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2621205062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621205062?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:44","pubTimestamp":1774356269,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0T1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061288","title":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061288?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:50","pubTimestamp":1774353049,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates Coverage on Generate Biomedicines With Overweight Rating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061159","title":"Generate Biomedicines Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061159?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:46","pubTimestamp":1774352760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 07:46 ET (11:46 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063010","title":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063010","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063010?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:17","pubTimestamp":1774347431,"startTime":"0","endTime":"0","summary":"Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621068889","title":"Generate Biomedicines initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621068889?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:15","pubTimestamp":1774343742,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $30 price target The firm has “high conviction in multi-blockbu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050714","title":"Generate Biomedicines initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621050714?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:00","pubTimestamp":1774342831,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff initiated coverage of Generate Biomedicines (GENB) with an Overweight rating and $24 price target The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621575470","title":"Generate Biomedicines initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621575470?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:35","pubTimestamp":1774341311,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $26 price target The company integrates generative AI models...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4543","LU2237438978.USD","BK4550","LU2237443622.USD","BK4139","BK4587","LU0345770993.USD","LU0061475181.USD","LU2237443465.HKD","LU2750360997.AUD","LU1868836914.USD","LU2471134952.CNY","LU2471134796.USD","LU1868837300.USD","LU1868836757.USD","LU1894683348.USD","BK4127","GSX","BK4588","BK4528","BK4504","BK4023","GENB","LU2237443895.HKD","LU1668664300.SGD","IE00B19Z3581.USD","LU0742534661.SGD","IE0034235188.USD","LU2750360641.GBP","BK4585","LU2471134523.USD","AI","IE00BSNM7G36.USD","BK4551","IE0004086264.USD","LU1791807156.HKD","IE00B19Z3B42.SGD","LU1868836591.USD","LU0251131958.USD","LU2237443382.USD","AIYY","LU0345770308.USD","LU0106831901.USD","IE0004091025.USD","LU2237443978.SGD","IE0002270589.USD","LU2471134879.HKD","BK4516","LU2265009873.SGD","LU0251142724.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621000051","title":"Generate Biomedicines Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2621000051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621000051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:43","pubTimestamp":1774338190,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B0RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621012051","title":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco","url":"https://stock-news.laohu8.com/highlight/detail?id=2621012051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621012051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:39","pubTimestamp":1774337945,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, SunocoMarch 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apogee","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL4N40C0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4504","KMI","GENB","LGND","BK4515","DAR","PFE","T","WEC","RL","ADM","SMCX","SUN","SMCL","BRX","SMCY","TSN","SMYY","ECL","VTRS","INSM","CF","RLMD","LU0354030511.USD","LU0690374961.EUR","VZ","XNCR","ACDC","REG","SMCI","SMCC","SPG","LU0496365809.HKD","BK4165","BG","SMCZ","MKC","CXW","CCL","STRO","DXCM","APGE","BK4189","SRZN","LW","FRT","APA","NCNO","NYT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":54,"code":"91000000","status":"200"}]}}